DMPK


Leadership:

  • Jeng-Pyng Shaw, Ph.D., executive director of DMPK
  • Song Zheng, M.S., assistant director of DMPK

Since 2006, BioDuro has been building in vitro ADME and PK study capabilities to support internal integrated medicinal chemistry programs and to provide a platform for external clients for early drug metabolism and pharmacokinetics (DMPK) screening. More than two-thirds of the team have postgraduate degrees and 15 percent have international training and/or experience.

We have established and validated a panel of in vitro assays, and provide services for international pharmaceutical and biotechnology companies. We offer a variety of services, including:

In vitro ADME

  • Physicochemical properties
    • Solubility
    • LogD
    • Chemical stability
    • Plasma stability
    • Plasma protein binding
  • In vitro drug metabolism
    • Liver microsome/hepatocyte stability
    • CYP phenotyping
    • Metabolite ID (Phase I and II)
  • Permeability
    • Caco-2
    • PAMPA
  • Drug-drug interaction
    • CYP inhibition assay

PK Studies

  • Small molecules and biologics
  • Various routes of administration
  • Crossover or noncrossover
  • Multiple cannulation procedures
  • Distribution in tissues
  • Metabolite identification
  • Bioanalytical method development, formulation development and bioanalysis
  • AAALAC accredited facilities